Kyverna Therapeutics, Inc.(KYTX)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Kyverna Therapeutics faces a high-risk financial profile characterized by the absence of commercial revenue and a persistent reliance on external financing to fund its broad autoimmune CAR T-cell therapy pipeline.
• While the company maintains a technical liquidity cushion, the rapid erosion of its cash position from $224.3M in 2024Q1 to $32.2M in 2026Q1 suggests that operational continuity is increasingly dependent on future capital raises.
• Investors should monitor the company's ability to reach clinical milestones before the current cash runway is fully exhausted by quarterly net losses that reached $39.7M in 2026Q1.